

September 2026

Uncovering new opportunities in a rapidly changing sector

Important Information

1. The Fund's investments in equities could incur significant losses due to higher fluctuation of equity values. The Fund's investments are concentrated in the healthcare, pharmaceuticals and other healthscience sectors. This may result in greater volatility than more broad-based investments.
2. The Fund is subject to currency risk, emerging market risk, foreign investments restrictions risk, small-cap companies' volatility and liquidity risks, securities lending counterparty risk and currency conversion risk including Renminbi denominated Classes.
3. **Class 10 Shares** pay dividends gross of expenses and/or from capital at the Directors' discretion. Paying dividends gross of expenses may result in more income being available for distribution; however these shares may effectively pay dividends from capital – may amount to a partial return or withdrawal of an investor's original investment or capital gains. All declared dividends result in an immediate reduction in the NAV price of the share class on the ex-dividend date.
4. The Fund may use derivatives for hedging and for investment purposes. However, usage for investment purposes will not be extensive. The Fund may suffer losses from its derivatives usage.
5. The value of the Fund can be volatile and can go down substantially within a short period of time. It is possible that a certain amount of your investment could be lost.
6. Investors should not make investment decisions based on this document alone. Investors should refer to the Prospectus and Key Facts Statement for details including risk factors.

Flexible and bottom-up investment approach

Aims to capture opportunities across all healthcare sub-sector

- Pharmaceuticals
- Healthcare Providers & Services
- Biotechnology
- Medical Devices & Supplies

690%

Cumulative return since inception (A2 USD)¹

Investment expertise

An average of 23 years of experience in scientific research, medicine and investing

Why invest?



3

1 Long term structural tailwinds on both demand and innovation

Healthcare demand growth is secular and visible – with global aging population and health innovation to drive the long term spending growth.



Demand – demographics & spending

- **20%** of the U.S. population aged 65+ by 2030 (vs 12% in 1985)*
- **3x** more healthcare spend for 65+ vs under-65^a




Supply – innovation & breakthroughs

- **Therapeutic innovation** – e.g. oncology, immunology, metabolic
- **Technology-enabled care** – e.g. diagnostics & robotic surgery
- **Platform innovation** – e.g. genetic medicines & AI

There is no guarantee that forecasts made will come to pass. For illustrative purposes only. Source: * S&P Global Market Intelligence, 14 Nov 2024. ^aCME, 13 Dec 2023 (NHE Factsheet).

2 Competitive valuation with solid fundamentals

Healthcare is not just a defensive sector but has also seen growth, with the majority of companies beating earnings expectations, and offers competitive valuations, trading at a discount to the broader market.



Left chart: Source: BlackRock, Bloomberg as of June 2026. Healthcare relative P/E premium/discount vs. the broad market since 1997; historical rebound figures reflect performance following the 2009 healthcare reform debate and the 2020 COVID-19 onset. Right chart: Source: FactSet as of Q2 2026. Percentage of MSCI World healthcare companies by sector beating consensus EPS estimates over the trailing four quarters.

Fund Data

Manager	Erin Xie/ Xiang Liu ⁴
Inception	06.04.2001
Currency	Unhedged: USD, EUR
	Hedged: AUD, EUR, HKD, JPY, SGD, RMB
Total Fund Size (m)	USD13,132.90
Annual Management Fee (Including Distribution fee, if any)	1.50%
Initial Charge	5%
Bloomberg Ticker	MEALU LX
ISIN Code	LU0122379950
NAV (USD)	79.05
Standard Deviation (3 years)	12.75%
Beta (3 years)	0.92

Composition of Fund (%)

Geography



United States	75.23
Switzerland	10.41
United Kingdom	4.07
Denmark	1.57
Belgium	1.54
Israel	0.99
China	0.96
Japan	0.77
Germany	0.74
France	0.46
Cash and/or Derivatives	3.26

Sector



Pharmaceuticals	45.65
Biotechnology	23.58
Life Sciences Tools & Services	11.55
Health Care Providers & Services	8.69
Health Care Equip. & Supplies	7.27
Cash and/or Derivatives	3.26

Allocations are subject to change. Due to rounding, the total may not be equal to 100%. Geographic exposure relates principally to the domicile of the issuers of the securities held in the product, added together and then expressed as a percentage of the product's total holdings. However, in some instances it can reflect the geography where the issuer of the securities carries out much of their business.

Investment Objective


BlackRock World Healthscience Fund seeks to maximize total return. The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed.

Cumulative & Annualized Performance in USD

	Cumulative (%)			Annualized (% p.a.)	
	YTD	6 Months	1 Year	3 Years	5 Years
Fund (A2)	+5.39	+3.01	+17.53	+6.88	+3.57

Calendar Year Performance in USD (%)

	2021	2022	2023	2024	2025
Fund (A2)	+14.19	-5.21	+2.18	+1.94	+13.09



Distribution Information

Ex-dividend date: 31.8.2026

Currency	Share Class	Frequency	Dividend	Yield (%) ⁵
USD	A10 Distributing (T)	Monthly	0.054500	6.53

10 Largest Holdings

Company	Weighting (%)
ELI LILLY	9.46
JOHNSON & JOHNSON	8.55
ABBVIE	6.32
MERCK & CO INC	5.58
ROCHE PS PAR AG	4.75
NOVARTIS AG	4.28
THERMO FISHER SCIENTIFIC INC	3.74
GILEAD SCIENCES	3.63
UNITEDHEALTH GROUP INC	3.55
AMGEN INC	3.32
Total	53.18

The Fund is actively managed and its composition will vary. Holdings shown are for illustrative purposes only and should not be deemed as a recommendation to buy or sell the securities listed. Fund details, holdings and characteristics are as of the date noted and subject to change. Holdings subject to change.

blackrock.com/hk | clientservice.asiapac@blackrock.com | +852 3903 2688

¹ Source: BlackRock, as of end August 2026. Past performance is not a guide to future performance. Investors may not get back the full amount invested. Performance is calculated based on the period NAV-to-NAV with dividend reinvested. Performance figures are calculated net of fees.

² Source: Morningstars, as of end August 2026.

³ Citywire Asia Asset Management Awards 2025 for the period from 30 June 2022 to 30 June 2025.

⁴ Prior to 27 June 2023, the Fund was managed by Erin Xie, Xiang Liu and Jeffrey Lee. Prior to 1 June 2020, the Fund was managed by Erin Xie.

⁵ A10 share class annualized yield = (Dividend rate/ex-date NAV) * (12*100). Inception date: A10 USD share class: 26 October 2022. Dividend yield is not guaranteed, and is not indicative of the return of the Fund. Past performance is not a guide to future performance. Investors may not get back the full amount invested.

Unless otherwise specified, all information applies to A2 USD share class only, as of end August 2026. Sources: BlackRock and Morningstar. Performance is shown as of the month end in share class currency on a NAV to NAV price basis with income reinvested, net of fees. The above Fund data is for information only and does not constitute an offer or invitation to anyone to invest in any BlackRock Global Funds (BGF) and has not been prepared in connection with any such offer. BGF is an open-ended investment company established in Luxembourg which is available for sale in certain jurisdictions only. BGF is not available for sale in the U.S. or to U.S. persons. Product information concerning BGF should not be published in the U.S. Investment involves risk. Past performance is not necessarily a guide to future performance or returns. The value of investments and the income from them can fluctuate and is not guaranteed. Rates of exchange may cause the value of investments to go up or down. Investors may not get back the amount they invest. Individual stock price/figure does not represent the return of the Fund. The investment returns are denominated in share class dealing currency, which may be a foreign currency. If so, US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar/foreign currency exchange rate. For Hong Kong investors, please refer to the BGF offering documents for details, including risk factors. Issued by BlackRock Asset Management North Asia Limited. This material and the BlackRock website (www.blackrock.com/hk) have not been reviewed by the Securities and Futures Commission of Hong Kong. ©2026 BlackRock, Inc. or its affiliates. All Rights Reserved. BLACKROCK is a registered trademark of BlackRock, Inc. or its affiliates. All other trademarks are those of their respective owners.